Table 3.

Number of patients with adjudicated on-trial relapse, by eculizumab exposure quartile.

Group	Total no. of patients	No. of patients with adjudicated on-trial relapse
Patients receiving placebo	47	20
Patients receiving eculizumab
Patients with AUCss within 1st quartile (range 58,714–143,644 μg·h/ml)	24	0
Patients with AUCss within 2nd quartile (range 144,679–179,692 μg·h/ml)	24	0
Patients with AUCss within 3rd quartile (range 181,113–216,888 μg·h/ml)	23	2
Patients with AUCss within 4th quartile (range 218,938–331,373 μg·h/ml)	24	1

AUC_ss was calculated using post-hoc pharmacokinetic parameters from the final population-pharmacokinetic model. One eculizumab-treated patient for whom no post-hoc pharmacokinetic parameters were obtained was excluded from the analysis.

AUC, area under the concentration–time curve within one dosing interval; ss, steady state.